Abstract

Prebeta1 HDL is the initial plasma acceptor of cell-derived cholesterol in reverse cholesterol transport. Recently, small amphipathic peptides composed of D-amino acids have been shown to mimic apolipoprotein A-I (apoA-I) as a precursor for HDL formation. ApoA-I mimetic peptides have been proposed to stimulate the formation of prebeta1 HDL and increase reverse cholesterol transport in apoE-null mice. The existence of a monoclonal antibody (MAb 55201) and a corresponding ELISA method that is selective for the detection of the prebeta(1) subclass of HDL provides a means of establishing a correlation between apoA-I mimetic dose and prebeta1 HDL formation in human plasma. Using this prebeta1 HDL ELISA, we demonstrate marked apoA-I mimetic dose-dependent prebeta1 HDL formation in human plasma. These results correlated with increases in band density of the plasma prebeta1 HDL, when observed by Western blotting, as a function of increased apoA-I mimetic concentration. Increased prebeta1 HDL formation was observed after as little as 1 min and was maximal within 1 h. Together, these data suggest that a high-throughput prebeta1 HDL ELISA provides a way to quantitatively measure a key component of the reverse cholesterol transport pathway in human plasma, thus providing a possible method for the identification of apoA-I mimetic molecules.

Highlights

  • Preb1 HDL is the initial plasma acceptor of cellderived cholesterol in reverse cholesterol transport

  • As the initial plasma acceptor of cholesterol from cell membranes [8], preb1 HDL is of particular interest as a biomarker for therapies targeting the antiatherosclerotic capabilities of HDL

  • To better understand the apolipoprotein A-I (apoA-I) content of preb1 HDL, apoA-I or D4F was incubated with human plasma and samples were analyzed by one-dimensional, nondenaturing, nonreducing Western blotting

Read more

Summary

Introduction

Preb HDL is the initial plasma acceptor of cellderived cholesterol in reverse cholesterol transport. The existence of a monoclonal antibody (MAb 55201) and a corresponding ELISA method that is selective for the detection of the preb subclass of HDL provides a means of establishing a correlation between apoA-I mimetic dose and preb HDL formation in human plasma. This ELISA may provide the chance to better understand the activity of potential Damino acid peptide therapies that have been shown to mimic the functionality of apoA-I in reverse cholesterol transport. In light of this possibility, we used this ELISA method to investigate the apoA-I mimetic dose-dependent formation of preb HDL in human plasma. This article is available online at http://www.jlr.org

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call